Article
Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer.
Cellular and molecular life sciences : CMLS - 3 Sept 2022
Zaballos Miguel A, Acuña-Ruiz Adrián, Morante Marta, Riesco-Eizaguirre Garcilaso, Crespo Piero, Santisteban Pilar
Abstract excerpt
BACKGROUND: RAS-to-ERK signaling is crucial for the onset and progression of advanced thyroid carcinoma, and blocking ERK dimerization provides a therapeutic benefit in several human carcinomas. Here we analyzed the effects of DEL-22379, a relatively specific ERK dimerization inhibitor, on the activation of the RAS-to-ERK signaling cascade and on tumor-related processes in vitro and in vivo. METHODS: We used a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.